ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Prostate Cancer PARP Inhibitor Drugs Market Research Report 2025
Published Date: May 2025
|
Report Code: QYRE-Auto-5T14179
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Prostate Cancer PARP Inhibitor Drugs Market Research Report 2023
BUY CHAPTERS

Global Prostate Cancer PARP Inhibitor Drugs Market Research Report 2025

Code: QYRE-Auto-5T14179
Report
May 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astrazeneca plc
Merck& Co. Inc
GSK
Pfizer Inc
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene Ltd
Jiangsu Hengrui Pharmaceuticals Co., Ltd

Prostate Cancer PARP Inhibitor Drugs Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Prostate Cancer PARP Inhibitor Drugs Market

Prostate Cancer PARP Inhibitor Drugs Market

The global market for Prostate Cancer PARP Inhibitor Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
Poly ADP-ribose polymerase (PARP) is a DNA repair enzyme involved in the single-strand repair process of DNA. PARP inhibitors (PARPi) inhibit PARP activity through two mechanisms: direct inhibition of PARP function and PARP trapping, resulting in the stalling and collapse of replication forks, resulting in fatal double-strand breaks. Normal cells can repair double-strand breaks in time and correctly through homologous recombination repair (HRR); however, in tumor cells carrying HRR gene mutations, due to the impairment or loss of HRR function, the accumulated double-strand breaks will not be repaired in time and correctly, resulting in The tumor cell genome is unstable and eventually induces tumor cell death.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Prostate Cancer PARP Inhibitor Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Prostate Cancer PARP Inhibitor Drugs.
The Prostate Cancer PARP Inhibitor Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Prostate Cancer PARP Inhibitor Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Prostate Cancer PARP Inhibitor Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Prostate Cancer PARP Inhibitor Drugs Market Report

Report Metric Details
Report Name Prostate Cancer PARP Inhibitor Drugs Market
CAGR 5%
Segment by Type
  • Lynparza
  • Zejula
  • Talzenna
  • Fluzoparib
  • PamiPali
  • Other
Segment by Application
  • Hospital
  • Specialty Clinic
  • other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc, Jiangsu Hengrui Pharmaceuticals Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Prostate Cancer PARP Inhibitor Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Prostate Cancer PARP Inhibitor Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Prostate Cancer PARP Inhibitor Drugs Market report?

Ans: The main players in the Prostate Cancer PARP Inhibitor Drugs Market are AstraZeneca, Merck & Co., Inc, GSK, Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company Limited, BeiGene, Inc, Jiangsu Hengrui Pharmaceuticals Co., Ltd

What are the Application segmentation covered in the Prostate Cancer PARP Inhibitor Drugs Market report?

Ans: The Applications covered in the Prostate Cancer PARP Inhibitor Drugs Market report are Hospital, Specialty Clinic, other

What are the Type segmentation covered in the Prostate Cancer PARP Inhibitor Drugs Market report?

Ans: The Types covered in the Prostate Cancer PARP Inhibitor Drugs Market report are Lynparza, Zejula, Talzenna, Fluzoparib, PamiPali, Other

Recommended Reports

PARP & DNA Repair

Prostate Cancer

Oncology Therapeutics

1 Prostate Cancer PARP Inhibitor Drugs Market Overview
1.1 Product Definition
1.2 Prostate Cancer PARP Inhibitor Drugs by Type
1.2.1 Global Prostate Cancer PARP Inhibitor Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Lynparza
1.2.3 Zejula
1.2.4 Talzenna
1.2.5 Fluzoparib
1.2.6 PamiPali
1.2.7 Other
1.3 Prostate Cancer PARP Inhibitor Drugs by Application
1.3.1 Global Prostate Cancer PARP Inhibitor Drugs Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Specialty Clinic
1.3.4 other
1.4 Global Prostate Cancer PARP Inhibitor Drugs Market Size Estimates and Forecasts
1.4.1 Global Prostate Cancer PARP Inhibitor Drugs Revenue 2020-2031
1.4.2 Global Prostate Cancer PARP Inhibitor Drugs Sales 2020-2031
1.4.3 Global Prostate Cancer PARP Inhibitor Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Prostate Cancer PARP Inhibitor Drugs Market Competition by Manufacturers
2.1 Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Prostate Cancer PARP Inhibitor Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Prostate Cancer PARP Inhibitor Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs, Product Type & Application
2.7 Global Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs, Date of Enter into This Industry
2.8 Global Prostate Cancer PARP Inhibitor Drugs Market Competitive Situation and Trends
2.8.1 Global Prostate Cancer PARP Inhibitor Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Prostate Cancer PARP Inhibitor Drugs Players Market Share by Revenue
2.8.3 Global Prostate Cancer PARP Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Prostate Cancer PARP Inhibitor Drugs Market Scenario by Region
3.1 Global Prostate Cancer PARP Inhibitor Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Prostate Cancer PARP Inhibitor Drugs Sales by Region: 2020-2031
3.2.1 Global Prostate Cancer PARP Inhibitor Drugs Sales by Region: 2020-2025
3.2.2 Global Prostate Cancer PARP Inhibitor Drugs Sales by Region: 2026-2031
3.3 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Region: 2020-2031
3.3.1 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Region: 2020-2025
3.3.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Region: 2026-2031
3.4 North America Prostate Cancer PARP Inhibitor Drugs Market Facts & Figures by Country
3.4.1 North America Prostate Cancer PARP Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2031)
3.4.3 North America Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Prostate Cancer PARP Inhibitor Drugs Market Facts & Figures by Country
3.5.1 Europe Prostate Cancer PARP Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2031)
3.5.3 Europe Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Prostate Cancer PARP Inhibitor Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Prostate Cancer PARP Inhibitor Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Prostate Cancer PARP Inhibitor Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Prostate Cancer PARP Inhibitor Drugs Market Facts & Figures by Country
3.7.1 Latin America Prostate Cancer PARP Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2031)
3.7.3 Latin America Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Prostate Cancer PARP Inhibitor Drugs Sales by Type (2020-2031)
4.1.1 Global Prostate Cancer PARP Inhibitor Drugs Sales by Type (2020-2025)
4.1.2 Global Prostate Cancer PARP Inhibitor Drugs Sales by Type (2026-2031)
4.1.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Type (2020-2031)
4.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Type (2020-2031)
4.2.1 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Type (2020-2025)
4.2.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Type (2026-2031)
4.2.3 Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Prostate Cancer PARP Inhibitor Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Prostate Cancer PARP Inhibitor Drugs Sales by Application (2020-2031)
5.1.1 Global Prostate Cancer PARP Inhibitor Drugs Sales by Application (2020-2025)
5.1.2 Global Prostate Cancer PARP Inhibitor Drugs Sales by Application (2026-2031)
5.1.3 Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Application (2020-2031)
5.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Application (2020-2031)
5.2.1 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Application (2020-2025)
5.2.2 Global Prostate Cancer PARP Inhibitor Drugs Revenue by Application (2026-2031)
5.2.3 Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Prostate Cancer PARP Inhibitor Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Company Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Merck & Co., Inc
6.2.1 Merck & Co., Inc Company Information
6.2.2 Merck & Co., Inc Description and Business Overview
6.2.3 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.2.5 Merck & Co., Inc Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GSK Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Johnson & Johnson
6.5.1 Johnson & Johnson Company Information
6.5.2 Johnson & Johnson Description and Business Overview
6.5.3 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.5.5 Johnson & Johnson Recent Developments/Updates
6.6 Takeda Pharmaceutical Company Limited
6.6.1 Takeda Pharmaceutical Company Limited Company Information
6.6.2 Takeda Pharmaceutical Company Limited Description and Business Overview
6.6.3 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.6.5 Takeda Pharmaceutical Company Limited Recent Developments/Updates
6.7 BeiGene, Inc
6.7.1 BeiGene, Inc Company Information
6.7.2 BeiGene, Inc Description and Business Overview
6.7.3 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.7.5 BeiGene, Inc Recent Developments/Updates
6.8 Jiangsu Hengrui Pharmaceuticals Co., Ltd
6.8.1 Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information
6.8.2 Jiangsu Hengrui Pharmaceuticals Co., Ltd Description and Business Overview
6.8.3 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product Portfolio
6.8.5 Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Prostate Cancer PARP Inhibitor Drugs Industry Chain Analysis
7.2 Prostate Cancer PARP Inhibitor Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Prostate Cancer PARP Inhibitor Drugs Production Mode & Process Analysis
7.4 Prostate Cancer PARP Inhibitor Drugs Sales and Marketing
7.4.1 Prostate Cancer PARP Inhibitor Drugs Sales Channels
7.4.2 Prostate Cancer PARP Inhibitor Drugs Distributors
7.5 Prostate Cancer PARP Inhibitor Drugs Customer Analysis
8 Prostate Cancer PARP Inhibitor Drugs Market Dynamics
8.1 Prostate Cancer PARP Inhibitor Drugs Industry Trends
8.2 Prostate Cancer PARP Inhibitor Drugs Market Drivers
8.3 Prostate Cancer PARP Inhibitor Drugs Market Challenges
8.4 Prostate Cancer PARP Inhibitor Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Astrazeneca plc
Merck& Co. Inc
GSK
Pfizer Inc
Johnson & Johnson
Takeda Pharmaceutical Company Limited
BeiGene Ltd
Jiangsu Hengrui Pharmaceuticals Co., Ltd
List of Tables
 Table 1. Global Prostate Cancer PARP Inhibitor Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Prostate Cancer PARP Inhibitor Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Prostate Cancer PARP Inhibitor Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Prostate Cancer PARP Inhibitor Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Prostate Cancer PARP Inhibitor Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Prostate Cancer PARP Inhibitor Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Prostate Cancer PARP Inhibitor Drugs Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Prostate Cancer PARP Inhibitor Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Prostate Cancer PARP Inhibitor Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Prostate Cancer PARP Inhibitor Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Prostate Cancer PARP Inhibitor Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Prostate Cancer PARP Inhibitor Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Prostate Cancer PARP Inhibitor Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Prostate Cancer PARP Inhibitor Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Prostate Cancer PARP Inhibitor Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Prostate Cancer PARP Inhibitor Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Prostate Cancer PARP Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Prostate Cancer PARP Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Prostate Cancer PARP Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Prostate Cancer PARP Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Prostate Cancer PARP Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Prostate Cancer PARP Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Prostate Cancer PARP Inhibitor Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Prostate Cancer PARP Inhibitor Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Prostate Cancer PARP Inhibitor Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Prostate Cancer PARP Inhibitor Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Prostate Cancer PARP Inhibitor Drugs Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Prostate Cancer PARP Inhibitor Drugs Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Prostate Cancer PARP Inhibitor Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Prostate Cancer PARP Inhibitor Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Prostate Cancer PARP Inhibitor Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Prostate Cancer PARP Inhibitor Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Prostate Cancer PARP Inhibitor Drugs Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Prostate Cancer PARP Inhibitor Drugs Price (US$/Unit) by Application (2026-2031)
 Table 70. AstraZeneca Company Information
 Table 71. AstraZeneca Description and Business Overview
 Table 72. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. AstraZeneca Prostate Cancer PARP Inhibitor Drugs Product
 Table 74. AstraZeneca Recent Developments/Updates
 Table 75. Merck & Co., Inc Company Information
 Table 76. Merck & Co., Inc Description and Business Overview
 Table 77. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Merck & Co., Inc Prostate Cancer PARP Inhibitor Drugs Product
 Table 79. Merck & Co., Inc Recent Developments/Updates
 Table 80. GSK Company Information
 Table 81. GSK Description and Business Overview
 Table 82. GSK Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. GSK Prostate Cancer PARP Inhibitor Drugs Product
 Table 84. GSK Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Pfizer Prostate Cancer PARP Inhibitor Drugs Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Johnson & Johnson Company Information
 Table 91. Johnson & Johnson Description and Business Overview
 Table 92. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Johnson & Johnson Prostate Cancer PARP Inhibitor Drugs Product
 Table 94. Johnson & Johnson Recent Developments/Updates
 Table 95. Takeda Pharmaceutical Company Limited Company Information
 Table 96. Takeda Pharmaceutical Company Limited Description and Business Overview
 Table 97. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Takeda Pharmaceutical Company Limited Prostate Cancer PARP Inhibitor Drugs Product
 Table 99. Takeda Pharmaceutical Company Limited Recent Developments/Updates
 Table 100. BeiGene, Inc Company Information
 Table 101. BeiGene, Inc Description and Business Overview
 Table 102. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. BeiGene, Inc Prostate Cancer PARP Inhibitor Drugs Product
 Table 104. BeiGene, Inc Recent Developments/Updates
 Table 105. Jiangsu Hengrui Pharmaceuticals Co., Ltd Company Information
 Table 106. Jiangsu Hengrui Pharmaceuticals Co., Ltd Description and Business Overview
 Table 107. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Jiangsu Hengrui Pharmaceuticals Co., Ltd Prostate Cancer PARP Inhibitor Drugs Product
 Table 109. Jiangsu Hengrui Pharmaceuticals Co., Ltd Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Prostate Cancer PARP Inhibitor Drugs Distributors List
 Table 113. Prostate Cancer PARP Inhibitor Drugs Customers List
 Table 114. Prostate Cancer PARP Inhibitor Drugs Market Trends
 Table 115. Prostate Cancer PARP Inhibitor Drugs Market Drivers
 Table 116. Prostate Cancer PARP Inhibitor Drugs Market Challenges
 Table 117. Prostate Cancer PARP Inhibitor Drugs Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Prostate Cancer PARP Inhibitor Drugs
 Figure 2. Global Prostate Cancer PARP Inhibitor Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Prostate Cancer PARP Inhibitor Drugs Market Share by Type: 2024 & 2031
 Figure 4. Lynparza Product Picture
 Figure 5. Zejula Product Picture
 Figure 6. Talzenna Product Picture
 Figure 7. Fluzoparib Product Picture
 Figure 8. PamiPali Product Picture
 Figure 9. Other Product Picture
 Figure 10. Global Prostate Cancer PARP Inhibitor Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 11. Global Prostate Cancer PARP Inhibitor Drugs Market Share by Application: 2024 & 2031
 Figure 12. Hospital
 Figure 13. Specialty Clinic
 Figure 14. other
 Figure 15. Global Prostate Cancer PARP Inhibitor Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 16. Global Prostate Cancer PARP Inhibitor Drugs Market Size (2020-2031) & (US$ Million)
 Figure 17. Global Prostate Cancer PARP Inhibitor Drugs Sales (2020-2031) & (K Units)
 Figure 18. Global Prostate Cancer PARP Inhibitor Drugs Average Price (US$/Unit) & (2020-2031)
 Figure 19. Prostate Cancer PARP Inhibitor Drugs Report Years Considered
 Figure 20. Prostate Cancer PARP Inhibitor Drugs Sales Share by Manufacturers in 2024
 Figure 21. Global Prostate Cancer PARP Inhibitor Drugs Revenue Share by Manufacturers in 2024
 Figure 22. Global 5 and 10 Largest Prostate Cancer PARP Inhibitor Drugs Players: Market Share by Revenue in Prostate Cancer PARP Inhibitor Drugs in 2024
 Figure 23. Prostate Cancer PARP Inhibitor Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 24. Global Prostate Cancer PARP Inhibitor Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 25. North America Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 26. North America Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 27. United States Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Canada Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Europe Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 30. Europe Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 31. Germany Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. France Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. U.K. Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Italy Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Russia Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Region (2020-2031)
 Figure 37. Asia Pacific Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Region (2020-2031)
 Figure 38. China Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Japan Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. South Korea Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. India Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Australia Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. China Taiwan Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Southeast Asia Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Prostate Cancer PARP Inhibitor Drugs Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. UAE Prostate Cancer PARP Inhibitor Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Prostate Cancer PARP Inhibitor Drugs by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Prostate Cancer PARP Inhibitor Drugs by Type (2020-2031)
 Figure 57. Global Prostate Cancer PARP Inhibitor Drugs Price (US$/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Prostate Cancer PARP Inhibitor Drugs by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Prostate Cancer PARP Inhibitor Drugs by Application (2020-2031)
 Figure 60. Global Prostate Cancer PARP Inhibitor Drugs Price (US$/Unit) by Application (2020-2031)
 Figure 61. Prostate Cancer PARP Inhibitor Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Global PARP Poly ADP ribose Polymerase Inhibitors Market Insights Forecast to 2030
DNA Repair PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Poly ADP Ribose Polymerase PARP Inhibitors Market Research Report 2024
PARP Inhibitors for Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global PARP Inhibitors for Breast Cancer Market Research Report 2024
Global PARP Poly ADP Ribose Polymerase Inhibitor Market Research Report 2025
Cancer Drug based on PARP Inhibitor Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Olaparib API Market Research Report 2024
Global Enzyme Poly ADP Ribose Polymerase PARP Inhibitor Market Insights Forecast to 2030
Global Niraparib API Market Research Report 2024
Global PARP Inhibitor Biomarkers Service Market Research Report 2024
Targeting DNA Repair Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
DNA Repair Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Enzyme Poly ADP Ribose Polymerase Inhibitor Market Insights Forecast to 2030
Global PARP Inhibitor Biomarkers Testing Product Market Research Report 2024
Global Niraparib Preparations Market Research Report 2024
Global PARP1 Antibody Market Research Report 2024
Global Platinum based Anticancer APIs Market Research Report 2024
Prostate Cancer Therapeutics Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Castrate resistant Prostate Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions